论文部分内容阅读
[目的]观察布拉氏酵母菌(亿活)对中度活动期溃疡性结肠炎(UC)患者的临床疗效。[方法]收集近年来(2014年10月~2016年3月)在我院经肠镜和病理检查并确诊为中度活动期的48例UC患者随机分为治疗组与对照组,每组患者均为24例,在接受治疗前分别对2组患者进行肠镜及主要症状两方面进行统计学分析,P>0.05,差异无统计学意义。治疗组予以口服美沙拉嗪缓释颗粒的基础上同时联合亿活治疗,对照组则单纯口服美沙拉嗪缓释颗粒,疗程均为3个月。服药期间每隔半月详细记录2组患者在服药期间的症状改善情况和实验相关指标的变化情况,在疗程结束一周内再次对2组患者行肠镜及黏膜病理学检查。[结果]两种治疗方法在主要临床症状改善情况、血清中hs-CRP、IL-4含量及肠黏膜愈合度、黏膜组织病理学方面均有治疗效果,均能促进炎症的吸收加速溃疡的愈合,但治疗组在缓解UC患者主要临床症状、实验相关指标及肠粘膜愈合方面明显优于对照组,(P<0.05)。[结论]亿活联合美沙拉嗪缓释颗粒治疗中度活动期溃疡性结肠炎临床疗效确切,值得推广应用。
[Objective] To observe the clinical curative effect of B. Saccharomyces in patients with moderate active ulcerative colitis (UC). [Methods] Forty-eight patients with UC who underwent colonoscopy and pathological examination in our hospital in recent years (October 2014 to March 2016) were randomly divided into treatment group and control group, and each group of patients All were 24 cases. Before the treatment, the two groups of patients underwent enteroscopy and the main symptoms were statistically analyzed, P> 0.05, the difference was not statistically significant. The treatment group was given oral mesalazine sustained release granules based on the combination of 100 million live treatment, while the control group was simply oral mesalazine sustained-release granules, treatment were 3 months. During the medication every half month, two groups of patients were recorded in detail during the medication to improve the symptoms and experimental indicators related to changes in the course of treatment within one week again, two groups of patients underwent colonoscopy and mucosal pathology. [Results] The two treatment methods were effective in improving the main clinical symptoms, serum levels of hs-CRP, IL-4, intestinal mucosa healing and mucosal histopathology, all of which could promote the absorption of inflammation and accelerate the healing of ulcer , But the treatment group was significantly better than the control group in alleviating the main clinical symptoms, experimental related indicators and intestinal mucosal healing of UC patients (P <0.05). [Conclusion] Billion live combined with mesalazine sustained release particles in the treatment of moderate active ulcerative colitis clinical curative effect is worthy of promotion.